QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, June 4, 2008, 28(23):6030-6036; doi:10.1523/JNEUROSCI.0891-08.2008

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Kim, J. Articles by Golde, T. E. PubMed PubMed Citation Articles by Kim, J. Articles by Golde, T. E. Pubmed/NCBI databases Gene GEO Profiles HomoloGene Nucleotide Protein UniGene

 Previous Article  |  Next Article 

Neurobiology of Disease
BRI2 (ITM2b) Inhibits Aβ Deposition In Vivo

Jungsu Kim,¹ Victor M. Miller,¹ Yona Levites,¹ Karen Jansen West,¹ Craig W. Zwizinski,¹ Brenda D. Moore,¹ Fredrick J. Troendle,¹ Maralyssa Bann,¹ Christophe Verbeeck,¹ Robert W. Price,¹ Lisa Smithson,¹ Leilani Sonoda,¹ Kayleigh Wagg,¹ Vijayaraghavan Rangachari,¹ Fanggeng Zou,¹ Steven G. Younkin,¹ Neill Graff-Radford,² Dennis Dickson,¹ Terrone Rosenberry,¹ and Todd E. Golde¹

Departments of ¹Neuroscience and ²Neurology, Mayo Clinic College of Medicine, Mayo Clinic Jacksonville, Jacksonville, Florida 32224

Correspondence should be addressed to either Terrone Rosenberry (regarding Aβ/Bri2-23 aggregation studies) or Todd E. Golde (all other correspondence), Department of Neuroscience, Mayo Clinic College of Medicine, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, Email: rosenberry{at}mayo.edu or Email: tgolde{at}mayo.edu

Analyses of the biologic effects of mutations in the BRI2 (ITM2b) and the amyloid β precursor protein (APP) genes support the hypothesis that cerebral accumulation of amyloidogenic peptides in familial British and familial Danish dementias and Alzheimer's disease (AD) is associated with neurodegeneration. We have used somatic brain transgenic technology to express the BRI2 and BRI2-Aβ1–40 transgenes in APP mouse models. Expression of BRI2-Aβ1–40 mimics the suppressive effect previously observed using conventional transgenic methods, further validating the somatic brain transgenic methodology. Unexpectedly, we also find that expression of wild-type human BRI2 reduces cerebral Aβ deposition in an AD mouse model. Additional data indicate that the 23 aa peptide, Bri23, released from BRI2 by normal processing, is present in human CSF, inhibits Aβ aggregation in vitro and mediates its anti-amyloidogenic effect in vivo. These studies demonstrate that BRI2 is a novel mediator of Aβ deposition in vivo.

Key words: BRI2; ITM2b; amyloid β protein; Alzheimer's disease; somatic brain transgenesis; adeno-associated virus

---

Received Feb. 28, 2008; revised May 2, 2008; accepted May 4, 2008.

Correspondence should be addressed to either Terrone Rosenberry (regarding Aβ/Bri2-23 aggregation studies) or Todd E. Golde (all other correspondence), Department of Neuroscience, Mayo Clinic College of Medicine, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, Email: rosenberry{at}mayo.edu or Email: tgolde{at}mayo.edu

This article has been cited by other articles:

				S. Matsuda, L. Giliberto, Y. Matsuda, E. M. McGowan, and L. D'Adamio BRI2 Inhibits Amyloid {beta}-Peptide Precursor Protein Processing by Interfering with the Docking of Secretases to the Substrate J. Neurosci., August 27, 2008; 28(35): 8668 - 8676. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help